Table II.
Adverse events.
| 1st LEN (n=39) | 2nd LEN (n=13) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||||
| Grade, n | Grade, n | ||||||||||
|
|
|
||||||||||
| Events | 1 | 2 | 3 | 4 | All grades (%) | 1 | 2 | 3 | 4 | All grades (%) | P-value |
| Leucopenia | 5 | 7 | 1 | 0 | 13 (33.3) | 2 | 1 | 1 | 0 | 4 (30.8) | 0.864 |
| Neutropenia | 2 | 6 | 3 | 0 | 11 (28.2) | 3 | 1 | 0 | 0 | 4 (30.8) | 0.860 |
| Platelet count decreased | 17 | 10 | 1 | 0 | 28 (71.8) | 5 | 3 | 1 | 0 | 9 (69.2) | 0.860 |
| Aspartate aminotransferase/alanine aminotransferase increased | 17 | 1 | 0 | 0 | 18 (46.2) | 7 | 0 | 3 | 0 | 10 (76.9) | 0.016a |
| Blood bilirubin increased | 10 | 6 | 2 | 0 | 18 (46.2) | 2 | 3 | 0 | 0 | 5 (38.5) | 0.629 |
| Anemia | 13 | 3 | 2 | 0 | 18 (46.2) | 4 | 3 | 0 | 0 | 7 (53.8) | 0.631 |
| Diarrhea | 5 | 0 | 1 | 0 | 6 (15.4) | 3 | 1 | 0 | 0 | 4 (30.8) | 0.244 |
| Nausea | 3 | 2 | 0 | 0 | 5 (12.8) | 1 | 0 | 0 | 0 | 1 (7.7) | 0.616 |
| Vomiting | 2 | 0 | 0 | - | 2 (5.1) | 0 | 0 | 0 | - | 0 | 0.405 |
| Fatigue | 11 | 4 | 1 | - | 16 (41.0) | 6 | 2 | 0 | - | 8 (61.5) | 0.199 |
| Proteinuria | 0 | 11 | 4 | - | 15 (38.5) | 2 | 0 | 3 | - | 5 (38.5) | 1 |
| Anorexia | 11 | 2 | 1 | 0 | 14 (35.9) | 5 | 0 | 0 | 0 | 5 (38.5) | 0.868 |
| Edema in limbs | 7 | 0 | 0 | - | 7 (17.9) | 5 | 0 | 0 | - | 5 (38.5) | 0.128 |
| Hypertension | 8 | 4 | 2 | 0 | 14 (35.9) | 1 | 0 | 0 | 0 | 1 (7.7) | 0.052 |
| Hand-foot-syndrome | 4 | 4 | 0 | - | 8 (20.5) | 4 | 1 | 0 | - | 5 (38.5) | 0.196 |
| Hoarseness | 1 | 0 | 0 | - | 1 (2.6) | 0 | 0 | 0 | - | 0 | 0.560 |
| Rash | 1 | 0 | 0 | 0 | 1 (2.6) | 0 | 0 | 0 | 0 | 0 | 0.560 |
| Musculoskeletal and connective tissue disorder | 2 | 0 | 0 | 0 | 2 (5.1) | 0 | 0 | 0 | 0 | 0 | 0.405 |
| Hypothyroidism | 2 | 3 | 0 | 0 | 5 (12.8) | 3 | 3 | 0 | 0 | 6 (46.2) | 0.011a |
| Epistaxis | 1 | 0 | 0 | 0 | 1 (2.6) | 0 | 0 | 0 | 0 | 0 | 0.560 |
| Oral pain | 2 | 0 | 0 | - | 2 (5.1) | 0 | 0 | 0 | - | 0 | 0.405 |
| Dizziness | 1 | 0 | 0 | - | 1 (2.6) | 0 | 0 | 0 | - | 0 | 0.560 |
| Abdominal pain | 2 | 0 | 0 | - | 2 (5.1) | 0 | 0 | 0 | - | 0 | 0.405 |
Fisher's exact probability tests.
a
P<0.05. Atez/BV, atezolizumab/bevacizumab; LEN, lenvatinib; CPK, creatine kinase. 1st LEN is a group in which lenvatinib was used as the first-line treatment. 2nd LEN is a group in which atezolizumab plus bevacizumab was used as the first-line treatment and lenvatinib was used as the second-line treatment.